JP2023542212A5 - - Google Patents
Info
- Publication number
- JP2023542212A5 JP2023542212A5 JP2023518392A JP2023518392A JP2023542212A5 JP 2023542212 A5 JP2023542212 A5 JP 2023542212A5 JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023542212 A5 JP2023542212 A5 JP 2023542212A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- bispecific antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20198050 | 2020-09-24 | ||
| EP20198050.5 | 2020-09-24 | ||
| EP20201583.0 | 2020-10-13 | ||
| EP20201583 | 2020-10-13 | ||
| EP21172627 | 2021-05-07 | ||
| EP21172627.8 | 2021-05-07 | ||
| PCT/EP2021/075995 WO2022063803A1 (en) | 2020-09-24 | 2021-09-22 | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542212A JP2023542212A (ja) | 2023-10-05 |
| JP2023542212A5 true JP2023542212A5 (https=) | 2024-09-30 |
Family
ID=78000677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518392A Pending JP2023542212A (ja) | 2020-09-24 | 2021-09-22 | Ｔ細胞二重特異性抗体に関連する有害作用の予防又は緩和 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220088195A1 (https=) |
| EP (1) | EP4216998A1 (https=) |
| JP (1) | JP2023542212A (https=) |
| KR (1) | KR20230074146A (https=) |
| CN (1) | CN116322691A (https=) |
| AU (1) | AU2021350075A1 (https=) |
| BR (1) | BR112023005399A2 (https=) |
| CA (1) | CA3193478A1 (https=) |
| IL (1) | IL300543A (https=) |
| MX (1) | MX2023003133A (https=) |
| TW (1) | TW202228773A (https=) |
| WO (1) | WO2022063803A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP4619428A1 (en) * | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Antigen binding molecules |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| EP3066130B1 (en) * | 2013-11-07 | 2019-05-15 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| US20200101108A1 (en) * | 2017-03-31 | 2020-04-02 | The Board Of Trustees Of The Le-Land Standford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| MX2020006119A (es) * | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| WO2020077258A1 (en) * | 2018-10-12 | 2020-04-16 | Jeanmarie Guenot | Cd33×cd3 binding proteins for treating inflammatory conditions and diseases |
-
2021
- 2021-09-22 KR KR1020237009954A patent/KR20230074146A/ko active Pending
- 2021-09-22 WO PCT/EP2021/075995 patent/WO2022063803A1/en not_active Ceased
- 2021-09-22 AU AU2021350075A patent/AU2021350075A1/en active Pending
- 2021-09-22 MX MX2023003133A patent/MX2023003133A/es unknown
- 2021-09-22 CN CN202180065376.9A patent/CN116322691A/zh active Pending
- 2021-09-22 IL IL300543A patent/IL300543A/en unknown
- 2021-09-22 BR BR112023005399A patent/BR112023005399A2/pt unknown
- 2021-09-22 EP EP21782915.9A patent/EP4216998A1/en active Pending
- 2021-09-22 CA CA3193478A patent/CA3193478A1/en active Pending
- 2021-09-22 JP JP2023518392A patent/JP2023542212A/ja active Pending
- 2021-09-23 TW TW110135298A patent/TW202228773A/zh unknown
- 2021-09-24 US US17/448,729 patent/US20220088195A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542212A5 (https=) | ||
| Messenheimer et al. | Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40 | |
| JP2024156736A5 (https=) | ||
| US9415104B2 (en) | Combination therapy to enhance NK cell mediated cytotoxicity | |
| Ma et al. | Tumor necrosis factor α blockade exacerbates murine psoriasis‐like disease by enhancing Th17 function and decreasing expansion of Treg cells | |
| JP2022050618A5 (https=) | ||
| US9561291B2 (en) | Methods of targeting T-cells to tumors | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| JP2016525117A5 (https=) | ||
| FI3844189T3 (fi) | Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää | |
| JP2016528195A5 (https=) | ||
| JP2017523187A5 (https=) | ||
| CN107847587A (zh) | Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗 | |
| JP2019525957A5 (https=) | ||
| JP2019526528A5 (https=) | ||
| JP2024507283A (ja) | 抗腫瘍薬を調製するための免疫療法薬と併用でのｐｐａｒ－デルタ阻害剤の使用 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| JP2021528393A (ja) | 後細胞シグナル伝達因子の調節による免疫活性の上昇 | |
| JP2018518465A5 (https=) | ||
| JP2023547523A5 (https=) | ||
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| US10611821B2 (en) | Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins | |
| CN116531503A (zh) | 抗-pd-1抗体及其在制备治疗胃癌患者的药物中的用途 | |
| JP2022554217A5 (https=) | ||
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof |